Cadrenal Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Cadrenal Therapeutics, Inc. (CVKD) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $16.93 per share as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $16.93.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $16.48.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $15.45.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $15.41.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $16.93 10-Q · filed 2026-08-13 |
| 2026-03-31 | $16.48 10-Q · filed 2026-05-07 |
| 2025-12-31 | $15.45 10-K · filed 2026-03-31 |
| 2025-09-30 | $15.41 10-Q · filed 2025-11-10 |
| 2025-06-30 | $14.58 10-Q · filed 2025-08-11 |
| 2025-03-31 | $13.72 10-Q · filed 2025-05-08 |
| 2024-12-31 | $12.80 10-K · filed 2025-03-13 |
| 2024-09-30 | $12.64 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.82 10-Q · filed 2024-08-07 |
| 2024-03-31 | $0.80 10-Q · filed 2024-05-09 |
| 2023-12-31 | $0.77 10-K · filed 2024-03-11 |
| 2023-09-30 | $0.64 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.64 10-Q · filed 2023-08-10 |
| 2023-03-31 | $0.64 10-Q · filed 2023-05-10 |
| 2022-12-31 | $0.64 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |